Brigatinib/Brigatinib (Brigatinib) efficacy

Brigatinib/Brigatinib (Brigatinib) is an oral anti-tumor drug mainly used to treat specific types of non-small cell lung cancer (NSCLC). Brigatinib/The main effects of Brigatinib include the following aspects:

1.Anti-tumor activity: Brigatinib/Brigatinib is mainly used to treat ALKfusion-positive NSCLC. By inhibiting ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) The activity of these two proteins, Brigatinib/Brigatinib can block the abnormal activation of cell signaling pathways and reduce the growth and spread of tumor cells. Brigatinib/Brigatinib can inhibit the development of tumors, slow down disease progression and prolong patient survival.

2.Effectiveness against ALKresistance mutations: For those who have received other ALK inhibitors and developed resistanceALK In pan>NSCLCpatients, Brigatinib/Brigatinib still has a certain efficacy. Brigatinib/Brigatinib can produce anti-tumor effects against some common ALK resistance mutations, such as ALK’s T790M mutation, and provide clinical benefits to these drug-resistant patients.

3.Therapeutic effect on EGFR mutations: Although the main indication of brigatinib/brigatinib is ALK fusion positiveNSCLC, some studies have also shown that it has certain anti-tumor activity against EGFR (epidermal growth factor receptor) mutated NSCLC. In patients who have failed or are resistant to EGFR inhibitors, brigatinib may be a viable alternative treatment option.

It should be noted that the efficacy of brigatinib/brigatinib may vary depending on individual patient differences, tumor characteristics and stage of treatment. Each patient's treatment plan should be evaluated and developed by a physician based on their specific circumstances.

The use of Brigatinib/Brigatinib should be conducted under the guidance of a physician and monitored and adjusted based on the patient's efficacy and tolerability. During treatment, patients should follow the doctor's advice, have regular follow-up visits, and promptly report any discomfort or side effects.

In general, Brigatinib/Brigatinib is an anti-cancer drug with anti-tumor activity, mainly used to treat ALK fusion-positive non-small cell lung cancer. It can prolong patient survival and produce efficacy in patients with ALK resistance and some EGFR mutations. However, outcomes may vary for each patient, and treatment should be individualized based on the patient's specific circumstances.

Brigatinib/Brigatinib has been launched in China and has been included in medical insurance. Since it has just been approved for marketing, patients may not be able to buy it in domestic pharmacies. If you need to purchase it in China, please consult the local pharmacy. However, the price is quite high, more than 10,000 yuan. Foreign Brigatinib/Brigatinib are mainly generic drugs, mainly from Bangladesh and Laos. The price of the international version of Bangladeshi generic drugs is high. About 2000yuan, specification: 90mg*30 tablets; the price of the Laos version of generic drugs is about 600Around, the specifications are smaller. And the ingredients of domestic original drugs and foreign generic drugs are basically the same.